Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
Completed · Phase 1
Conditions studied: Solid Tumors, Hematologic Malignancies, Hepatic Impairment
In brief
The purpose of this study is to compare the safety and efficacy of carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with varying degrees of liver function to see if they respond differently to the study drug.
Key facts
- Study ID
- NCT01949545
- Run by
- Amgen
- People needed
- 46
- Starts
- 2013-10-01
- Expected to finish
- 2015-09-01
- Last updated by the study team
- 2017-05-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Duke Cancer Institute — Durham, North Carolina, United States
- Gabrail Cancer Center — Canton, Ohio, United States
- Tennessee Oncology, PLLC — Nashville, Tennessee, United States
- Evergreen Hematology and Oncology — Spokane, Washington, United States
- Institut Gustave Roussy — Paris, Villejuif Cedex, France
- University Medical Centre Utrecht — Utrecht, Netherlands
- Northern Ireland Cancer Trials Centre - Queen's University Belfast TriaIs Centre — Belfast, Northern Ireland, United Kingdom
- Beatson West of Scotland Cancer Centre — Glasgow, Scotland, United Kingdom
- Velindre Hospital — Cardlff, Wales, United Kingdom
- Sir Bobby Robson Cancer Trials Research Centre — Newcastle, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.